Sign up
Pharma Capital

Physiomics reports record year of income with significant contract wins

Jim Millen, chief executive of Physiomics Plc (LON:PYC), tells Proactive's Andrew Scott revenues almost doubled last year, bolstered by the signing of a lucrative contract with German firm Merck KGaA.

The company, whose technology can help to predict the effect of a drug on cancer, saw its total income jump 90% to £513,000 in the year ended June 30 (2017: £270,500).

 

View full PYC profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.